此前报道： 两资产挂牌无人问津就再打折！永和智控"割肉求生" 永和智控12月17日晚间发布的关于公开挂牌转让普乐新能源科技(泰兴)有限公司51%股权及债权的进展公告。公司于2025年10月召开的董、监事会及临时 股东大会审议通过了《关于拟公开挂牌转让普乐新能源科技(泰兴)有限公司51%股权及债权的议案》，同意公司在产权交易所公开挂牌转让控股子公司普 乐新能源科技(泰兴)有限公司(以下简称"泰兴普乐")51%股权及公司对泰兴普乐的全部债权。 公告显示，前四次公开挂牌后，均无意向受让方报名参与投资。公司继续推进公开挂牌转让泰兴普乐51%股权及债权事项，根据董事会批准及授权，挂牌 价格在首次挂牌价格(3046万元)基础上，下调80%进行第五次挂牌，第五次挂牌转让底价为609.80万元。挂牌公告期为2025年12月17日起至2025年12月23 日止。 永和智控12月17日晚间还发布了关于公开挂牌转让昆明医科肿瘤医院有限公司100%股权的进展公告。公司于2025年11月18日召开的董、监事会审议通过 了《关于拟公开挂牌转让昆明医科肿瘤医院有限公司100%股权的议案》，同意公司在产权交易所公开挂牌转让全资孙公司昆明医科 ...

Core Viewpoint - Yonghe Intelligent Control Co., Ltd. is divesting all its investments in private oncology hospitals, marking a complete exit from the healthcare sector due to ongoing financial struggles and poor performance of its medical assets [2][3][5]. Group 1: Divestment Details - Yonghe Intelligent Control has initiated the public transfer of 100% equity in its wholly-owned subsidiary, Kunming Medical Oncology Hospital, with a starting price of no less than 35.93 million yuan [3][4]. - This divestment is part of a broader strategy, as Yonghe has already attempted to sell its stakes in three other oncology hospitals since 2020, including Dazhou Medical Oncology Hospital, Liangshan High-tech Oncology Hospital, and Xi'an Medical Oncology Hospital [3][4]. - The financial performance of Kunming Medical has been poor, with revenues of 11.58 million yuan and a net loss of 6.59 million yuan for the first seven months of 2025, contributing to Yonghe's decision to sell [3][6]. Group 2: Financial Performance - Yonghe Intelligent Control's main business includes fluid control products, oncology precision radiation treatment, and photovoltaic battery production. The company reported a revenue of 1.01 billion yuan in 2021, marking a 55.71% increase [5]. - However, the company's financial situation deteriorated significantly from 2022 to 2024, with revenues declining from 990 million yuan in 2022 to 823 million yuan in 2024, and net losses increasing from 26.19 million yuan to 297 million yuan during the same period [6]. - The decline in performance is attributed to reduced income from the valve and fitting business, lower product gross margins, and high depreciation and labor costs [6][7]. Group 3: Strategic Shift - Following the divestment of its medical assets, Yonghe Intelligent Control is expected to refocus on its core business operations. The company has not yet communicated its future strategic direction or potential new growth areas [7].

Core Viewpoint - Yonghe Intelligent Control is facing significant challenges in asset divestiture and ongoing financial losses, indicating a deteriorating business situation and lack of investor interest in its assets [1][2][3]. Group 1: Asset Transfer Attempts - Yonghe Intelligent Control announced the public transfer of 51% equity in Taixing Pule and all debts owed by Taixing Pule, with an initial listing price of RMB 30.49 million, but failed to attract any interested buyers [1][3]. - Following the lack of interest, the company plans a second round of asset transfer at a reduced price of RMB 24.39 million, reflecting a 20% decrease from the initial price [1][3]. - The company's previous attempt to transfer shares held by its actual controller was also unsuccessful, as the buyer failed to make the required payment, rendering the agreement void [1][9]. Group 2: Financial Performance - Yonghe Intelligent Control has experienced a continuous decline in revenue since 2022, with reported revenues of RMB 9.90 billion, RMB 9.48 billion, and RMB 8.23 billion for the years 2022, 2023, and 2024 respectively, showing year-on-year declines of -1.86%, -4.19%, and -13.19% [2][7]. - The company reported net losses of RMB 261.87 million, RMB 1.56 billion, and RMB 2.97 billion for the same years, with losses increasing significantly year-on-year [2][7]. - For the first three quarters of 2025, Yonghe Intelligent Control reported revenues of RMB 5.82 billion, a decrease of 7.25% year-on-year, and a net loss of RMB 60.46 million, although this loss was less than the previous year's figure [8]. Group 3: Company Background and Business Operations - Yonghe Intelligent Control's main business includes water and heating valve fittings, tumor precision radiation treatment, and photovoltaic cell operations, with a focus on brass and copper products [7]. - The company acquired a 51% stake in Taixing Pule in late 2022 for RMB 31.22 million, aiming to enter the photovoltaic cell industry, but has since struggled with the performance of this investment [5][8]. - As of May 31, 2025, Taixing Pule reported a net asset value of -RMB 304 million and a debt of RMB 185 million, leading to a high debt-to-asset ratio of 211% [4].

Core Viewpoint - The leading valve and fittings company Yonghe Zhikong is undergoing a change in control, with its major shareholder transferring shares to Hangzhou Runfeng, which has not yet commenced operations [1][6]. Group 1: Share Transfer Details - On August 5, the controlling shareholder Cao Deli signed a share transfer agreement to sell 35.66 million shares (8.00% of total shares) to Hangzhou Runfeng at a price of 8.9736 yuan per share, totaling 320 million yuan [1][2]. - Following the transfer, Hangzhou Runfeng will hold 8.00% of Yonghe Zhikong, and Sun Rongxiang will become the actual controller of the company, holding 14.65% of voting rights [3][4]. Group 2: Business Operations and Financial Performance - Yonghe Zhikong's main business includes plumbing valves and fittings, as well as tumor precision radiation treatment, with plans to divest from the photovoltaic and medical sectors by December 20 [4]. - The company has reported declining performance over the past three years, with net losses of 26.70 million yuan in 2022, 156 million yuan in 2023, and an expected loss of 297 million yuan in 2024 [4]. - For the first half of 2025, Yonghe Zhikong anticipates revenue between 330 million yuan and 380 million yuan, with a projected net loss of 30 million to 56 million yuan, primarily due to reduced income from valve fittings and declining gross margins [4]. Group 3: Legal Issues - Yonghe Zhikong and its subsidiaries are involved in multiple lawsuits, with a total amount of 64.83 million yuan in undisclosed litigation over the past twelve months, exceeding 10% of the company's latest audited net assets [5]. Group 4: Hangzhou Runfeng Background - Hangzhou Runfeng was established on July 22, 2023, with a registered capital of 20 million yuan, but has not yet engaged in any business activities related to industrial robots [6][7]. - The controlling shareholder of Hangzhou Runfeng is Hangzhou Yuli Enterprise Management Co., which was founded shortly before Runfeng and is linked to Sun Rongxiang [6][7].